Laboratorios Almirall, S.A.
Records under this name other than patents Laboratorios Almirall, S.A. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Back to Laboratorios Almirall, S.A.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,051,851 | Inhaler for the Administration of Powdered Pharmaceuticals, and a Powder Cartridge System for Use with This Inhaler Formerly held In force · High confidence | In force | High confidence | |
| US 7,964,615 | Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the β2 adrenergic receptor Formerly held In force · USPTO record | In force | USPTO record | |
| US 8,044,205 | Process for manufacturing 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane bromide Formerly held In force · USPTO record | In force | USPTO record | |
| US 8,258,308 | Amino nicotinic and isonicotinic acid derivatives as DHODH inhibitors Formerly held In force · USPTO record | In force | USPTO record | |
| US 8,420,669 | Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the BETA2 adrenergic receptor Lapsed on the fee record Ended Apr 16, 2025 · USPTO record | Lapsed on the fee record | Ended Apr 16, 2025 | USPTO record |
| US 6,681,768 | Powder Formulation Disintegrating System and Method for Dry Powder Inhalers Formerly held Term ended Term ended Aug 7, 2022 · High confidence | Term ended | Term ended Aug 7, 2022 | High confidence |
| US 7,214,687 | Quinuclidine derivatives and medicinal compositions containing the same Formerly held Term ended Term ended Aug 18, 2020 · USPTO record | Term ended | Term ended Aug 18, 2020 | USPTO record |
| US 7,078,412 | Quinuclidine derivatives and medicinal compositions containing the same Formerly held Term ended Term ended Jul 16, 2020 · USPTO record | Term ended | Term ended Jul 16, 2020 | USPTO record |
| US 7,196,098 | Quinuclidine derivatives and medicinal compositions containing the same Formerly held Term ended Term ended Jul 7, 2020 · USPTO record | Term ended | Term ended Jul 7, 2020 | USPTO record |
| US 7,750,023 | Quinuclidine derivatives and medicinal compositions containing the same Term ended Ended no later than Jul 7, 2020 · USPTO record | Term ended | Ended no later than Jul 7, 2020 | USPTO record |